VALUE IN HEALTH 19 (2016) Available online at journal homepage:
|
|
- Kelley McDowell
- 6 years ago
- Views:
Transcription
1 VALUE IN HEALTH 19 (2016) Available online at journal homepage: Comparison of Daily versus Weekly Recording of Gastroesophageal Reflux Disease Symptoms in Patients with a Partial Response to Proton Pump Inhibitor Therapy Anna Rydén, PhD 1, *, Olivia C. Leavy, MSc 2, Katarina Halling, MSc 1, Arthur A. Stone, PhD 3 1 AstraZeneca Gothenburg, Mölndal, Sweden; 2 Oxford Brookes University, Oxford, UK; 3 Department of Psychology and the USC Dornsife Center for Self-Report Science, University of Southern California, Los Angeles, CA, USA ABSTRACT Background: The Reflux Symptom Questionnaire electronic Diary (RESQ-eD) and the Reflux Symptom Questionnaire 7-day recall (RESQ-7) are versions of a patient-reported outcome instrument that was developed and validated for measuring the frequency and intensity of symptoms in patients with gastroesophageal reflux disease (GERD) who have a partial response to proton pump inhibitor (PPI) therapy. Objective: The aim of these analyses was to assess the ability of the RESQ-7 to reproduce findings based on RESQ-eD reports of the same symptoms. Methods: These analyses are based on data from patients with GERD with a partial response to PPI (ClinicalTrials. gov identifier: NCT ). Participants completed the RESQ-eD twice daily for 7 days and the RESQ-7 on day 7. Results: Data from 446 patients were available for these analyses. Symptom-level analyses showed that, for intensity, mean domain scores were higher for the RESQ-7 (range ) than for the RESQ-eD (range ); for frequency, scores were lower for the RESQ-7 (range ) than for the RESQ-eD (range ). Correspondence analyses of RESQ-7 and RESQ-eD mean domain scores indicated excellent agreement for intensity (correlation-concordance coefficient ) and fair agreement for frequency (correlation-concordance coefficient ). Mean RESQ-eD subscale intensity scores for GERD symptoms were higher for symptoms experienced during the daytime than for those occurring at nighttime. Symptom recall was not associated with peak or recency effects. Conclusions: Patients with GERD slightly overestimated the intensity of their reflux symptoms and markedly underestimated the frequency on weekly recall compared with twicedaily reporting. Keywords: ecological validity, frequency, gastroesophageal reflux disease, intensity, patient-reported outcome instruments. Copyright & 2016, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. Introduction Having valid and reliable patient-reported outcome (PRO) instruments for measuring symptoms is paramount in medical research. Disease-specific PRO instruments are developed for particular target populations, and it is thus crucial that they capture the complete symptom pattern of the group of patients of interest [1]. The recall period is also an important aspect of a PRO instrument, and depends on the target population, symptoms, and the general setting in which the PRO instrument is to be implemented. Memory biases (cognitive heuristics) tend to affect retrospective evaluation of symptoms, with the majority of individuals being disproportionately influenced by the most intense and the most recent symptom events when asked to recall the average intensity of symptoms, an effect termed the peak end rule [2 4]. In its guidance for industry, the US Food and Drug Administration recommends that questionnaires generally use short recall periods or ask patients to describe their current or recent state [5]. Asking patients to think back over a long period can reduce the accuracy of recall for all but the most memorable or stressful events [6], and may also make it more likely that the response is influenced by the patients current state [7]. Patients with gastroesophageal reflux disease (GERD) typically have troublesome symptoms of heartburn and regurgitation [8], which usually resolve with proton pump inhibitor (PPI) therapy [9,10]. Results from a systematic review indicated that about 20% to 30% of patients with GERD who participated in primary care Ethical approval: These post hoc analyses are based on data from the Patient-Reported Outcome Validation Study (ClinicalTrials.gov identifier: NCT ). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study. Conflict of interest: A. Rydén and K. Halling are employees of AstraZeneca Gothenburg, Mölndal, Sweden. O. C. Leavy is an MSc graduate from Oxford Brookes University, Oxford, UK. Arthur A. Stone is a consultant for ERT Inc. and is a Senior Scientist with the Gallup Organization. * Address correspondence to: Anna Rydén, AstraZeneca Gothenburg, S , Mölndal, Sweden. anna.ryden@astrazeneca.com $36.00 see front matter Copyright & 2016, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
2 830 VALUE IN HEALTH 19 (2016) studies had persistent heartburn or regurgitation during PPI therapy [11]. Symptoms confirmed by patients with a partial response to PPIs as being relevant to their GERD experience, in addition to heartburn and regurgitation, are hoarseness, cough, difficulty swallowing, and burping [12]. Most patients with GERD report having both daytime and nighttime symptoms [13]. Although the nature of daytime and nighttime GERD symptoms is similar in individuals with a partial response to PPI therapy, one study has reported a greater focus by patients on symptom intensity at night than during the day [14]. This increased attention paid to symptom intensity at night compared with during the day could potentially overestimate nighttime versus daytime symptom intensity on retrospective evaluation. PRO instruments for evaluating GERD symptoms are used to measure symptom intensity and frequency in clinical trial settings, and are valuable tools when assessing symptoms and deciding on disease management in primary care [6]. When asking patients to recall their GERD symptoms, the duration of the recall period used may be influenced by practical considerations. While daily electronic diaries provide an effective way of assessing conditions such as GERD, in which symptoms fluctuate from day to day [15], this short recall period may not be practical for use in routine clinical practice or in pragmatic clinical trials, for which questionnaires with a 7-day recall period are commonly used. The Reflux Symptom Questionnaire electronic Diary (RESQ-eD) and the Reflux Symptom Questionnaire 7-day recall (RESQ-7) are PRO instruments that were developed and validated for measuring the intensity and frequency of GERD symptoms in patients with a partial response to PPIs [12,16]. Both versions of the instrument are conceptually and structurally identical. However, the RESQ-eD uses a twice-daily electronic recording, which makes it preferable in the clinical trial setting, whereas the RESQ- 7 uses a 1-week recall period, making it more practical in routine clinical care [12,16]. The aim of the post hoc analyses presented in this article was to assess the ability of the RESQ-7 to reproduce faithfully findings based on twice-daily RESQ-eD reports of the same symptoms (i.e., its ecological validity [17]), using data from a large clinical study [16]. First, basic questions about the comparability and correlation of mean levels of aggregated real-time and recall measures were considered separately for intensity and frequency. Next, cognitive heuristics (peak and recency effects) that may be at work in the recall measures were assessed. Last, the role of nighttime symptoms in recall was examined. Methods Participants These post hoc analyses are based on data from part 1 (8 12-day screening phase) of the PRO Validation Study, which included patients with GERD who had a partial response to PPI therapy (N ¼ 580; mean age 48 years [range years]; 58% women; ClinicalTrials.gov identifier: NCT ) [16]. To be eligible for inclusion in the PRO Validation Study, patients had to have a history of GERD symptoms for at least 6 months and a minimum of 4 weeks of PPI therapy. Patients must have also reported (using the RESQ-7) a minimum of 3 days on which they experienced an at least mildly intense burning feeling behind the breastbone, and/or unpleasant movement of material upward from the stomach over the previous 7 days. Measures Participants completed the RESQ-eD twice daily during the screening phase (in the morning and before bedtime) and the RESQ-7 at the end of the screening phase. The RESQ-eD and the RESQ-7 were developed and validated for use in clinical trials in patients with a partial response to PPI therapy [12,16]. Both versions have the same 13 symptom items and use the same intensity scoring. However, the RESQ-eD is a twice-daily diary, whereas the RESQ-7 has a 7-day recall period. For each version of the instrument, the 13 symptom items combine into four separate domains: Heartburn (five items: burning feeling behind breastbone; pain behind breastbone; heartburn; burning feeling in upper stomach; and pain in upper stomach); Regurgitation (four items: acid taste in mouth; bitter taste in mouth; unpleasant movement of material upward from the stomach; and stomach contents [liquid or food] moving upward to throat or mouth); Hoarseness, cough, difficulty swallowing (three items: hoarseness; cough; and difficulty swallowing); and Burping (one item: burping). The intensity of each symptom item is recorded using a six-point scale (0 ¼ did not have; 1 ¼ very mild; 2 ¼ mild; 3 ¼ moderate; 4 ¼ moderately severe; and 5 ¼ severe). The RESQ-7 also captures information on symptom frequency during the past week (have not had; 1 day; 2 days; 3 4 days; 5 6 days; daily [with a day being defined as a 24-hour period]). Symptom Analyses For RESQ-eD symptom analyses, data were assessed for the 7 days ending with the last day of the screening phase (i.e., the 7 days covered by the RESQ-7 recall period). Each day was defined as the 24-hour period covered by the symptom scores reported on the RESQ-eD in the evening (which covered symptoms experienced during the daytime) and those reported the next morning (which covered symptoms experienced during the preceding nighttime). Daily (i.e., 24-hour) RESQ-eD symptom intensity was defined in the PRO Validation Study as the higher of the two daily item intensity scores (i.e., either the evening score or the following morning score, whichever was the higher). Mean weekly RESQ-eD symptom intensity was defined as the mean of the daily (24-hour) intensities during the week. Daily RESQ-eD domain intensity was defined as the mean (morning and evening) intensity values for all the items in that domain. Mean weekly RESQ-eD domain intensity was defined as the mean of the daily domain intensities during the week. RESQ-eD symptom frequency was computed on the basis of RESQ-eD intensity scores, with a daily item intensity score of at least very mild (score Z1) indicating a symptomatic day for that symptom item. For domain frequency, an intensity score of at least very mild on a particular day for any item in that domain was taken as indicating a day with symptoms for that domain. Statistical Analyses To be included in the analyses, patients had to have completed both the RESQ-eD and the RESQ-7 during the screening phase. Imputation was performed on the RESQ-eD data set if a single observation was missing in the sequence of morning or evening registrations, by replacing the missing value with the larger of the two surrounding values. If two or more consecutive observations were missing, no imputation was performed and the patient was excluded from these analyses. Mean SD domain scores were calculated for the RESQ-eD and the RESQ-7. For weekly frequency data from the RESQ-7, midpoints were created for the RESQ-7 response options 3 to 4 days (3.5 days) and 5 to 6 days (5.5 days). For the weekly frequency data from the RESQ-eD, the variable was categorized such that the 3-day response option and the 4-day response option were recoded into the 3- to 4-day interval, and the 5-day
3 VALUE IN HEALTH 19 (2016) response option and the 6-day response option were recoded into the 5- to 6-day interval, and the midpoints were then used. For correlation and symptom-level analyses, RESQ-eD intensity and frequency scores were compared using correlationconcordance coefficient (CCC) analyses and the paired t test, respectively. Given their similarity, CCC values were interpreted using the same ranges as used for standard intraclass correlation coefficient values (i.e., , fair-to-good; 40.75, excellent) [18 20]. To assess cognitive heuristics, day 7 (recency) and maximum (peak) diary day intensity scores for the RESQ-eD were compared with mean RESQ-7 intensity scores. Mean evening RESQ-eD intensity scores (i.e., for symptoms experienced during the day) and mean morning RESQ-eD intensity scores (i.e., for symptoms experienced during the night) for each of the four symptom domains were assessed for comparability both during days 1 to 3 and during days 5 to 7, using the paired t test. In addition, the comparability of mean evening and mean morning intensity scores on days 1 to 3 versus on days 5 to 7 was assessed for each of the four symptom domains, using the paired t test. Results Data Characteristics Of the 580 patients who participated in part 1 of the PRO Validation Study, 46 (8%) discontinued prematurely. A further 88 patients (15%) were excluded, either because they had two or more consecutive observations missing on the RESQ-eD (e.g., they were missing observations for the first day or the last day of the screening phase) or because they did not complete the RESQ-7 at the end of the screening phase. A total of 446 patients (77%) completed both the RESQ-eD and the RESQ-7 as required, and were thus included in these analyses. The mean age of included patients was years and 40% were men. Correlation Analyses The CCC for mean intensity ranged from 0.77 to 0.83 for the four symptom domains (Table 1), indicating excellent correlation between the RESQ-eD and the RESQ-7 for each of the four domains for symptom intensity. For mean frequency, the CCC ranged from 0.40 to 0.58 for the four symptom domains (Table 2), indicating fair correlation between the RESQ-eD and the RESQ-7 for each of the four domains for symptom frequency. Differences in Symptom Level between the RESQ-eD and the RESQ-7 Mean domain scores for intensity were lower for the RESQ-eD than for the RESQ-7 (Table 1). Paired t-test results for intensity showed a significant difference between mean RESQ-eD and RESQ-7 scores for each of the domains Heartburn, Regurgitation, and Burping (all P o 0.001; Table 1). Intensity scores did not differ significantly for the Hoarseness, cough, difficulty swallowing domain (P ¼ 0.277). Mean domain scores for frequency were higher for the RESQ-eD than for the RESQ-7 (Table 2). Paired t-test results for frequency showed a significant difference between mean RESQ-eD and RESQ-7 scores for all four domains (all P o 0.001). Table 1 Level and correspondence analyses of mean, day 7, and peak RESQ-eD vs RESQ-7 domain intensity scores. Domain/statistics Mean RESQ-eD vs RESQ-7 (n ¼ 446) Day 7 RESQ-eD vs RESQ-7 (n ¼ 436) Peak RESQ-eD vs RESQ-7 (n ¼ 446) Heartburn RESQ-eD score RESQ-7 score Score difference t 5.47 * 7.06 * * CCC Regurgitation RESQ-eD score RESQ-7 score Score difference t 4.47 * 5.71 * * CCC Hoarseness, cough, difficulty swallowing RESQ-eD score RESQ-7 score Score difference t * CCC Burping RESQ-eD score RESQ-7 score Score difference t * * CCC CCC, correlation-concordance coefficient; RESQ-eD, Reflux Symptom Questionnaire electronic Diary; RESQ-7, Reflux Symptom Questionnaire 7-day recall. * P o P o 0.05.
4 832 VALUE IN HEALTH 19 (2016) Table 2 Level and correspondence analyses of RESQ-eD vs RESQ-7 domain frequency scores (n ¼ 446). Domain/statistics Frequency (d/wk) Heartburn RESQ-eD score, mean SD RESQ-7 score, mean SD Score difference 1.49 t * CCC 0.42 Regurgitation RESQ-eD score, mean SD RESQ-7 score, mean SD Score difference 1.62 t * CCC 0.50 Hoarseness, cough, difficulty swallowing RESQ-eD score, mean SD RESQ-7 score, mean SD Score difference 1.64 t * CCC 0.58 Burping RESQ-eD score, mean SD RESQ-7 score, mean SD Score difference 1.42 t * CCC 0.40 CCC, correlation-concordance coefficient; RESQ-eD, Reflux Symptom Questionnaire electronic Diary; RESQ-7, Reflux Symptom Questionnaire 7-day recall. * P o Testing of Cognitive Heuristics Potential recency heuristic was assessed by comparing intensity scores for the last diary day (RESQ-eD day 7) with the weekly recall (RESQ-7). Mean RESQ-eD day 7 intensity scores differed significantly from mean RESQ-7 intensity scores for each of the four symptom domains (Table 1). The CCC values ranged from 0.68 to 0.78, indicating mostly fair-to-good correlation. Potential peak heuristic was assessed by comparing maximum diary day intensity scores with the weekly recall (RESQ-7). Maximum RESQ-eD diary day intensity scores differed significantly from mean RESQ-7 intensity scores for each of the four symptom domains (Table 1). The CCC values ranged from 0.63 to 0.71, indicating fair-to-good correlation. Comparability of Nighttime and Daytime Symptoms Mean evening RESQ-eD intensity scores (i.e., for symptoms experienced during the day) were significantly higher than mean morning RESQ-eD intensity scores (i.e., for symptoms experienced during the night) for each of the four symptom domains, both during days 1 to 3 (Heartburn: t ¼ 8.810; Regurgitation: t ¼ 4.833; Hoarseness, cough, difficulty swallowing: t ¼ 4.603; Burping: t ¼ ; all P o 0.001; df ¼ 445) and during days 5 to 7 (Heartburn: t ¼ 9.315; Regurgitation: t ¼ 6.955; Hoarseness, cough, difficulty swallowing: t ¼ 5.704; Burping: t ¼ ; all P o 0.001; df ¼ 445). For each of the four symptom domains, mean morning RESQeD intensity scores were not significantly different for days 1 to 3 versus days 5 to 7 (paired t test, Heartburn: t ¼ [P ¼ 0.067]; Regurgitation: t ¼ [P ¼ 0.912]; Hoarseness, cough, difficulty swallowing: t ¼ [P ¼ 0.628]; Burping: t ¼ [P ¼ 0.933]; df ¼ 445). For three of the four symptom domains, mean evening RESQ-eD intensity scores were not significantly different for days 1 to 3 versus days 5 to 7 (Regurgitation: t ¼ [P ¼ 0.480]; Hoarseness, cough, difficulty swallowing: t ¼ [P ¼ 0.500]; Burping: t ¼ [P ¼ 0.257]; df ¼ 445). However, the difference between mean intensity scores for days 1 to 3 versus days 5 to 7 was borderline significant for Heartburn (t ¼ [P ¼ 0.047]; df ¼ 445). Discussion In these analyses, patients with GERD slightly overestimated the intensity of their reflux symptoms and markedly underestimated symptom frequency on weekly recall when compared with daily reporting. Correlation between the mean RESQ-eD scores and RESQ-7 scores was excellent for symptom intensity, suggesting that individuals with high (or low) scores on the RESQ-eD also had high (or low) scores on the RESQ-7. The correlation for symptom frequency was only fair ( moderate ). The slightly higher symptom intensity reported on weekly recall compared with daily reporting is not surprising, and is consistent with other studies assessing recall periods for pain, headache, respiratory symptoms, fatigue, and the impact of symptoms on daily life [2,21 24]. In the current analyses, the difference in mean domain intensity scores between the two versions of the instrument was small, differing by, at most, 0.16 units on a scale ranging from 0 to 5. Thus, although patients overestimated the intensity of their GERD symptoms on weekly recall compared with daily reporting, the discrepancy was slight and is unlikely to be of much relevance in clinical practice, although it could be important in clinical trials. On average, patients were worse at recalling the frequency than the intensity of their symptoms. Mean domain scores for frequency (which could range from 0 to 7 d/wk) were between 1.42 and 1.64 d/wk lower for the RESQ-7 than for the RESQ-eD. Thus, patients tended to underestimate the number of days per week on which they experienced symptoms by about 1.5 days when recalling their GERD symptoms from the previous week. Few published data are available regarding the effects of recall period on the reporting of symptom frequency [24,25]. Generally, the recalling of frequency information is affected more by omission than by inappropriate inflation, leading to underestimation rather than overestimation when recalling symptom frequency [25]. However, in a study conducted in patients with migraine, a similar mean headache frequency was obtained from daily and 4-weekly reporting (15.1 vs 14.7 days in the 4-week period, respectively) [24], suggesting that effects of recall period on reporting of symptom frequency may depend on the type of symptom that is being assessed. In that study, the accuracy of recall was not affected by whether symptoms occurred more or less frequently [24]. The discrepancy between daily reporting and weekly recall of symptom frequency supports the use of the RESQ-eD rather than the RESQ-7 for assessing GERD symptom frequency in the clinical trial setting. With its longer recall period, the RESQ-7 still has a place in routine clinical practice or when conducting large, pragmatic trials, where weekly recording may be more practical than daily recording; however, patients underestimation of GERD symptom frequency on recall needs to be kept in mind when interpreting results. Our analyses went beyond the basic question of ecological validity and examined cognitive heuristics that may be at work in the RESQ-eD. Retrospective reporting of symptom intensity has been reported to be associated with the level of the most intense ( peak ) event that occurred during the recall period, an effect that is likely to be exacerbated by patients ignoring occasions when the symptom is absent, thus giving peak events undue
5 VALUE IN HEALTH 19 (2016) influence [2]. Symptom recall can also be affected by the level of intensity of the most recent ( end ) event [25]. In the current analyses, both maximum RESQ-eD intensity scores and intensity scores recorded on day 7 on the RESQ-eD differed significantly from mean RESQ-7 intensity scores for each of the four symptom domains. Thus, neither the maximum symptom intensity nor the intensity on the last day of reporting had a pronounced influence on recall. Agreement of both peak RESQ-eD scores and day 7 RESQ-eD scores with mean RESQ-7 scores was fair-toexcellent, indicating that the peak daily symptom score and the score on the last day of reporting correlated well with the weekly recall. Mean RESQ-eD domain intensity scores for GERD symptoms were higher for the evening reporting (which covered symptoms experienced during the daytime) than for the morning reporting (which covered symptoms experienced during the preceding nighttime). In contrast, information gathered as part of an interview study in individuals with a partial response to PPI therapy showed that patients experienced a greater intensity of heartburn and regurgitation during the night than during the day [14]. In that study, patients reported that the most troublesome effect of GERD symptoms on their daily lives was the impact on sleep [14]. A strength of our post hoc analyses is that they included a well-defined patient population. Limitations are that they were not originally planned as part of the PRO Validation Study, and that they did not compare the use of the RESQ-eD and the RESQ-7 for capturing changes over time. Such data would be of particular relevance when considering the suitability of these tools for assessing response to treatment. The need to recode response options for weekly symptom frequency to allow comparison between the two instruments presents another potential limitation. In conclusion, patients with GERD slightly overestimated the intensity of their reflux symptoms and markedly underestimated the frequency when recalling symptoms from the previous week. Symptom recall using the RESQ-7 was not associated with peak or recency effects. Acknowledgment We thank Dr. Reza Oskrochi for his supervision of Olivia C. Leavy s MSc project. Source of financial support: This study was funded by Astra- Zeneca Gothenburg, Sweden. Writing support was provided by Dr. Anja Becher, from Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca Gothenburg, Sweden. REFERENCES [1] Vakil NB, Halling K, Becher A, Rydén A. Systematic review of patientreported outcome instruments for gastroesophageal reflux disease symptoms. Eur J Gastroenterol Hepatol 2013;25:2 14. [2] Stone AA, Broderick JE, Shiffman SS, Schwartz JE. Understanding recall of weekly pain from a momentary assessment perspective: absolute agreement, between- and within-person consistency, and judged change in weekly pain. Pain 2004;107:61 9. [3] Stone AA, Broderick JE, Kaell AT, et al. Does the peak-end phenomenon observed in laboratory pain studies apply to real-world pain in rheumatoid arthritics? J Pain 2000;1: [4] Stone AA, Schwartz JE, Broderick JE, Shiffman SS. Variability of momentary pain predicts recall of weekly pain: a consequence of the peak (or salience) memory heuristic. Pers Soc Psychol Bull 2005;31: [5] Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims Available from: Drugs/.../Guidances/UCM pdf. [Accessed March 11, 2015]. [6] Chassany O, Shaheen NJ, Karlsson M, et al. Systematic review: symptom assessment using patient-reported outcomes in gastroesophageal reflux disease and dyspepsia. Scand J Gastroenterol 2012;47: [7] Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 2009;25: [8] Vakil N, Veldhuyzen van Zanten S, Kahrilas P, et al. The Montreal definition and classification of gastro-esophageal reflux disease (GERD) a global evidence-based consensus. Am J Gastroenterol 2006;101: [9] van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H 2 -receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004;4:CD [10] Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;2:CD [11] El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010;32: [12] Rydén A, Denison H, Karlsson M, Vakil N. Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. Scand J Gastroenterol 2013;48: [13] Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98: [14] Rydén A, Martin M, Halling K, Niklasson A. Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study. Patient 2013;6: [15] McColl E. Best practice in symptom assessment: a review. Gut 2004;53 (Suppl. 4):iv [16] Vakil N, Bjorck K, Denison H, et al. Validation of the reflux symptom questionnaire electronic diary in partial responders to proton pump inhibitor therapy. Clin Transl Gastroenterol 2012;3:e7. [17] Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol 2008;4:1 32. [18] Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Control Clin Trials 1991;12(Suppl. 4):142S 58. [19] Bennett AV, Patrick DL, Bushnell DM, et al. Comparison of 7-day and repeated 24-h recall of type 2 diabetes. Qual Life Res 2011;20: [20] Fleiss JL. The Design and Analysis of Clinical Experiments (Wiley Classics Library ed.). New York: Wiley, [21] Broderick JE, Schneider S, Schwartz JE, Stone AA. Interference with activities due to pain and fatigue: accuracy of ratings across different reporting periods. Qual Life Res 2010;19: [22] Broderick JE, Schwartz JE, Vikingstad G, et al. The accuracy of pain and fatigue items across different reporting periods. Pain 2008;139: [23] Bennett AV, Amtmann D, Diehr P, Patrick DL. Comparison of 7-day recall and daily diary reports of COPD symptoms and impacts. Value Health 2012;15: [24] McKenzie JA, Cutrer FM. How well do headache patients remember? A comparison of self-report measures of headache frequency and severity in patients with migraine. Headache 2009;49: [25] Gorin AA, Stone AA. Recall biases and cognitive errors in retrospective self-reports: a call for momentary assessments. In: Baum A, Revenson TA, Singer JE, eds., Handbook of Health Psychology. Mahwah, NJ: Erlbaum, 2001.
Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease
Volume 11 Number 4 2008 VALUE IN HEALTH Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease Ola Junghard, PhD, 1 Ingela Wiklund, PhD
More informationORIGINAL ARTICLES ALIMENTARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:612 619 ORIGINAL ARTICLES ALIMENTARY TRACT Regurgitation Is Less Responsive to Acid Suppression Than Heartburn in Patients With Gastroesophageal Reflux
More informationNimish Vakil 1*, Anna Niklasson 2, Hans Denison 2 and Anna Rydén 2
Vakil et al. BMC Gastroenterology 2014, 14:177 RESEARCH ARTICLE Open Access Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal
More informationPatient-reported Outcomes
3 Patient-reported Outcomes Ingela Wiklund Key points Many gastrointestinal diseases are symptomdriven, so the patient s perspective is particularly important in this area. Patient-reported outcomes (PROs)
More informationACID REFLUX & GERD: The Unsettling Reality in Canada
ACID REFLUX & GERD: The Unsettling Reality in Canada gerd fact 1 see page 8 Canadian Society of Intestinal Research On average, ARD patients wait over two years before seeking care 1. 1 gerd fact 2 see
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationComparison of 7-Day Recall and Daily Diary Reports of COPD Symptoms and Impacts
Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Comparison of 7-Day Recall and Daily Diary Reports of COPD Symptoms and Impacts Antonia V. Bennett, PhD 1, *, Dagmar
More informationUnderstanding gastro-oesophageal reflux disease: a patient-cluster analysis
ORIGINAL PAPER Understanding gastro-oesophageal reflux disease: a patient-cluster analysis A. King, 1 C. MacDonald, 1 C. Örn 2 doi: 10.1111/j.1742-1241.2008.01929.x OnlineOpen: This article is available
More information1 Introduction. David A. Johnson 1 Anne Le Moigne. Peter Nagy 3
Clin Drug Investig (2016) 36:531 538 DOI 10.1007/s40261-016-0398-7 ORIGINAL RESEARCH ARTICLE Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and
More informationComparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis
Journal of Cystic Fibrosis 9 (2010) 419 424 www.elsevier.com/locate/jcf Original Article Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis Antonia V. Bennett a,, Donald L.
More informationGastroesophageal reflux disease (GERD) is a condition. Effects of Gastroesophageal Reflux Disease on Sleep and Outcomes. Methods Study Design
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:953 959 Effects of Gastroesophageal Reflux Disease on Sleep and Outcomes REEMA MODY,* SUSAN C. BOLGE, HEMA KANNAN, and RONNIE FASS *Takeda Pharmaceuticals
More informationThe Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis and Non-Erosive Reflux Disease
ARC Journal of Hepatology and Gastroenterology Volume 1, Issue 1, 2016, PP 3-8 www.arcjournals.org The Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis
More informationNexium 24HR Pharmacy Training
Nexium 24HR Pharmacy Training Your pharmacist's advice is required. Always read the label. Use only as directed. If symptoms persist, consult your doctor/ healthcare professional. Pfizer Consumer Healthcare
More informationGastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) Acid Reflux Acid reflux occurs when acid from the stomach moves backwards into the esophagus. Heartburn Heartburn is a symptom of acid reflux and GERD. It may feel
More informationFDA s GREAT Workshop. Industry Perspective: Development Activities Towards Phase 3 Endpoints. September 19, 2012
FDA s GREAT Workshop Industry Perspective: Development Activities Towards Phase 3 Endpoints Malcolm Hill, Pharm.D. Meritage Pharma, Inc. San Diego, CA 09/19/12 1 September 19, 2012 Presentation Overview
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationHeartburn is a common symptom among adults in
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:553 563 Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials KENNETH R. MCQUAID*, and LOREN LAINE
More informationHold the Wrap! There is so much more to be done!
Hold the Wrap! There is so much more to be done! (Well, a few things that can be done.) (Well, not all that much, really ) (But Blair has never killed anyone with a PPI!) Nicholas Shaheen, MD, MPH Center
More informationDrug Class Review Proton Pump Inhibitors
Drug Class Review Proton Pump Inhibitors Evidence Tables April 2009 Update 4: May 2006 Update 3: May 2005 Update 2: April 2004 Update 1: April 2003 Original Report: November 2002 The literature on this
More informationComparison of Clinical Findings with Symptom Assessment Systems (GerdQ and FSSG) for Functional Gastrointestinal Diseases
ORIGINAL PAPER Surg. Gastroenterol. Oncol. 2018;23(3):198-203 DOI: 10.21614/sgo-23-3-198 Comparison of Clinical Findings with Symptom Assessment Systems (GerdQ and FSSG) for Functional Gastrointestinal
More informationACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease
ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease Philip O. Katz MD 1, Lauren B. Gerson MD, MSc 2 and Marcelo F. Vela MD, MSCR 3 1 Division of Gastroenterology, Einstein
More information282 Journal of Pain and Symptom Management Vol. 46 No. 2 August 2013
282 Journal of Pain and Symptom Management Vol. 46 No. 2 August 2013 Brief Report Comparing the Retrospective Reports of Fatigue Using the Fatigue Symptom Index With Daily Diary Ratings in Women Receiving
More informationDavid A. Peura 1,5*, Anne Le Moigne 2, Heather Wassel 3 and Charles Pollack 4
Peura et al. BMC Gastroenterology (2018) 18:69 https://doi.org/10.1186/s12876-018-0790-2 RESEARCH ARTICLE Open Access Sustained efficacy following resolution of frequent heartburn with an over-thecounter
More informationAccepted Article. Questionnaires for the diagnosis of gastroesophageal reflux disease: are they really useful? Constanza Ciriza de los Ríos
Accepted Article Questionnaires for the diagnosis of gastroesophageal reflux disease: are they really useful? Constanza Ciriza de los Ríos DOI: 10.17235/reed.2016.4267/2016 Link: PDF Please cite this article
More informationPage 1. Objectives. The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in Frequent Heartburn
Page 1 The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in Colin W. Howden, MD, FRCP
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationInterventional procedures guidance Published: 16 December 2015 nice.org.uk/guidance/ipg540
Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease Interventional procedures guidance Published: 16 December 2015 nice.org.uk/guidance/ipg540 Your
More informationRelieving Frequent Heartburn Day Through Night
Page 1 Relieving Frequent Heartburn Day Through Night Relieving Frequent Heartburn Day Through Night David Metz, MD Professor of Medicine University of Pennsylvania School of Medicine Philadelphia, PA
More informationPREPARING FOR REFLUX TESTING. Digitrapper Reflux Testing System
PREPARING FOR REFLUX TESTING Digitrapper Reflux Testing System An innovative solution to evaluate your gastroesophageal reflux symptoms on or off anti-reflux therapy WHY TEST FOR GERD? Do you have frequent
More informationRefractory GERD: What s a Gastroenterologist To Do?
Refractory GERD: What s a Gastroenterologist To Do? Philip O. Katz, MD, FACG Chairman, Division of Gastroenterology Einstein Medical Center Clinical Professor of Medicine Jefferson Medical College Philadelphia,
More informationRefractory GERD : case presentation and discussion
Refractory GERD : case presentation and discussion Ping-Huei Tseng National Taiwan University Hospital May 19, 2018 How effective is PPI based on EGD? With GERD symptom 75% erosive 25% NERD Endoscopy 81%
More informationQuality of life in patients with gastroesophageal reflux disease in an Iranian population
Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Quality of life in patients with gastroesophageal reflux disease
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationAlimentary Pharmacology & Therapeutics SUMMARY
Alimentary Pharmacology & Therapeutics Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayedrelease esomeprazole capsules on nocturnal
More informationOTC PPI Therapy in Frequent Heartburn
Page 1 Gate Keeper to the Appropriate Use of OTC PPI Therapy for Conflicts of Interest Gatekeeper to the Appropriate Use of OTC PPI Therapy in Colin W. Howden, MD, FRCP (Glasg), FACP, FACG, FCP Professor
More informationBRAVO. ph Monitoring System. A patient-friendly test for heartburn
BRAVO ph Monitoring System A patient-friendly test for heartburn Bravo ph Monitoring System Why Test for Heartburn? Do you have a great deal of indigestion or a burning sensation in the center of your
More informationCMEARTICLE. WHAT CAN I DO IN MY PRACTICE? History. Daphne Ang 1, MBBS, FRCP (Edin), Choon How How 2, MMed, FCFP, Tiing Leong Ang 1, MBBS, FRCP (Edin)
Singapore Med J 2016; 57(10): 546-551 10.11622/smedj.2016167 CMEARTICLE Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy Daphne Ang 1, MBBS, FRCP (Edin), Choon How How
More informationRepeatability of a questionnaire to assess respiratory
Journal of Epidemiology and Community Health, 1988, 42, 54-59 Repeatability of a questionnaire to assess respiratory symptoms in smokers CELIA H WITHEY,' CHARLES E PRICE,' ANTHONY V SWAN,' ANNA 0 PAPACOSTA,'
More informationA model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?
Alimentary Pharmacology and Therapeutics A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? P. O. Katz*, D. A. Johnson
More informationPREPARING FOR REFLUX TESTING. Bravo Reflux Testing System. A simple way to evaluate your gastroesophageal reflux symptoms
PREPARING FOR REFLUX TESTING Bravo Reflux Testing System A simple way to evaluate your gastroesophageal reflux symptoms HOW IT WORKS The test involves a miniature ph capsule, which is approximately the
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European
More informationHealth-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia
Aliment Pharmacol Ther 23; 17: 835 84. doi: 1.146/j.269-2813.23.1497.x Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia A. QUADRI & N. VAKIL University of Wisconsin
More informationA Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori- Negative Primary Care Patients with Dyspepsia in Japan
Gut and Liver, Vol. 7, No. 1, January 2013, pp. 16-22 ORiginal Article A Study on the Efficacy of Proton Pump Inhibitors in Helicobacter pylori- Negative Primary Care Patients with Dyspepsia in Japan Tomoari
More informationFour-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1083 1088 Four-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy IKUO HIRANO, QING ZHANG, JOHN E. PANDOLFINO, and PETER J. KAHRILAS
More informationGERD is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications
GERD is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications Esophageal Syndromes Extra - esophageal Syndromes Symptomatic Syndromes Typical reflux
More informationBruley des Varannes et al. BMC Gastroenterology 2013, 13:39
Bruley des Varannes et al. BMC Gastroenterology 2013, 13:39 RESEARCH ARTICLE Open Access Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor
More informationNonerosive reflux disease as a presentation of gastro-oesophageal reflux disease
Nonerosive reflux disease as a presentation of gastro-oesophageal reflux disease Abstract Simmonds WM, MMed (Internal Medicine) Gastroenterology Fellow, Department of Internal Medicine, Free State University
More information235 60th Street, West New York, NJ T: (201) F: (201) Main Street, Hackensack, NJ T: (201)
235 60th Street, West New York, NJ 07093 T: (201) 854-4646 F: (201) 854-4647 810 Main Street, Hackensack, NJ 07601 T: (201) 488-0095 Barrett's Esophagus WHAT IS BARRETTT'S ESOPHAGUS? Barrett's esophagus
More informationTypically characterized by frequent or troublesome heartburn REVIEW
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:816 822 REVIEW What Makes Individuals With Gastroesophageal Reflux Disease Dissatisfied With Their Treatment? PETER BYTZER Department of Medical Gastroenterology,
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More informationTLESR, transient lower esophageal sphincter relaxation.
GASTROENTEROLOGY 2010;139:409 417 CLINICAL Effects of Lesogaberan on Reflux and Lower Esophageal Sphincter Function in Patients With Gastroesophageal Reflux Disease GUY E. BOECKXSTAENS,*, HANNEKE BEAUMONT,*
More informationMaximizing Outcome of Extraesophageal Reflux Disease. (GERD) is often accompanied
...PRESENTATIONS... Maximizing Outcome of Extraesophageal Reflux Disease Based on a presentation by Peter J. Kahrilas, MD Presentation Summary Gastroesophageal reflux disease (GERD) accompanied by regurgitation
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationPutting Chronic Heartburn On Ice
Putting Chronic Heartburn On Ice Over the years, gastroesophageal reflux disease has proven to be one of the most common complaints facing family physicians. With quicker diagnosis, this pesky ailment
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Evidence Tables July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May 2005
More informationThe Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease
Volume 12 Number 1 2009 VALUE IN HEALTH The Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease Antoine Gosselin, MA,
More informationStudy population The study population comprised a hypothetical cohort of patients with confirmed reflux oesophagitis.
Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Wahlqvist P, Junghard O, Higgins A, Green J Record Status This is a critical
More informationGastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) Information for patients UHN Read this handout to learn about: What gastroesohageal reflux (GERD) is Signs and symptoms How your doctor will know if you have it Tests
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationAssessment of reflux symptom severity: methodological options and their attributes
iv28 Assessment of reflux symptom severity: methodological options and their attributes P Bytzer... Despite major advances in our understanding of reflux disease, the management of this disorder still
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationFunctional Heartburn and Dyspepsia
Functional Heartburn and Dyspepsia Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina Objectives Understand the means of diagnosing functional heartburn
More informationPrevalence and Clinical Characteristics of Refractoriness to Optimal Proton Pump Inhibitor Therapy in Non-erosive Reflux Disease
www.medscape.com Prevalence and Clinical Characteristics of Refractoriness to Optimal Proton Pump Inhibitor Therapy in Non-erosive Reflux Disease Mentore Ribolsi; Michele Cicala; Patrizia Zentilin; Matteo
More informationBurning Issues in Gastroesophageal Reflux Disease (GERD)
3:45 4:45pm Burning Issues in GERD SPEAKER Prateek Sharma, MD, FACG, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Prateek Sharma, MD, FACG, FACP,
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More informationJNM Journal of Neurogastroenterology and Motility
JNM Journal of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol. 19 No. 1 January, 2013 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm.2013.19.1.61 Original Article Comparison
More informationORIGINAL INVESTIGATION. The Impact of Nocturnal Symptoms Associated With Gastroesophageal Reflux Disease on Health-Related Quality of Life
ORIGINAL INVESTIGATION The Impact of Nocturnal Symptoms Associated With Gastroesophageal Reflux Disease on Health-Related Quality of Life Christina Farup, MD; Leah Kleinman, DrPH; Sheldon Sloan, MD; Dara
More informationLaryngopharyngeal Reflux
Laryngopharyngeal Reflux The Silent Reflux What is Laryngopharyngeal Reflux? Also called Reflux laryngitis, laryngopharyngeal reflux is a condition where the acid from the stomach reaches the voicebox
More informationA multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis
J Gastroenterol (14) 49:1536 1547 DOI 1.17/s535-13-925-8 ORIGINAL ARTICLE ALIMENTARY TRACT A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief
More informationOptimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI
Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University
More information1. Introduction. Correspondence should be addressed to Wei-Chen Tai; Received 29 May 2013; Accepted 5 July 2013
Gastroenterology Research and Practice Volume 2013, Article ID 480325, 6 pages http://dx.doi.org/10.1155/2013/480325 Clinical Study The Frequencies of Gastroesophageal and Extragastroesophageal Symptoms
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationSystematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease
Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease Guy E Boeckxstaens, Smout J Smout To cite this version: Guy E Boeckxstaens, Smout J Smout. Systematic
More informationJuly 19, Division of Dockets Management Food and Drug Administration 5630 Fishers Lane Room 1061, HFA-305 Rockville, Maryland 20852
July 19, 2017 Division of Dockets Management Food and Drug Administration 5630 Fishers Lane Room 1061, HFA-305 Rockville, Maryland 20852 Re: Comments on Citizen s Petition #FDA-2017-P-2733 Herein, the
More informationDepression and treatment with antidepressants are associated with the development of gastro-oesophageal reflux disease
Alimentary Pharmacology & Therapeutics Depression and treatment with antidepressants are associated with the development of gastro-oesophageal reflux disease E. MARTÍN-MERINO*, A. RUIGÓMEZ*,L.A.GARCÍARODRÍGUEZ*,
More informationWHAT IS GASTROESOPHAGEAL REFLUX DISEASE (GERD)?
WHAT IS GASTROESOPHAGEAL REFLUX DISEASE (GERD)? The term gastroesophageal reflux describes the movement (or reflux) of stomach contents back up into the esophagus, the muscular tube that extends from the
More informationThe Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal Reflux Disease
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 160-164 ORiginal Article The Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal
More informationTreatment Options for GERD or Acid Reflux Disease A Review of the Research for Adults
Treatment Options for GERD or Acid Reflux Disease A Review of the Research for Adults hur till återvinna från prostataoperation Is This Information Right for Me? Yes, if: A doctor said that you have gastroesophageal
More informationGERD. Gastroesophageal reflux disease, or GERD, occurs when acid from the. stomach backs up into the esophagus. Normally, food travels from the
GERD What is GERD? Gastroesophageal reflux disease, or GERD, occurs when acid from the stomach backs up into the esophagus. Normally, food travels from the mouth, down through the esophagus and into the
More informationNon-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics
Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic
More informationEffect of Esomeprazole 40 mg Once or Twice Daily on Asthma A Randomized, Placebo-controlled Study
Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma A Randomized, Placebo-controlled Study Toni O. Kiljander 1, Ola Junghard 2, Ola Beckman 2, and Tore Lind 2 1 Department of Respiratory Medicine,
More informationReview article: alternative approaches to the long-term management of GERD
Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 39 44. Review article: alternative approaches to the long-term management of GERD M. B. FENNERTY Division of Gastroenterology, Oregon Health and Science University,
More informationNational Digestive Diseases Information Clearinghouse
Barrett s Esophagus National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is Barrett s esophagus? Barrett s esophagus is
More informationAlginates Extended Abstract
Alginates Extended Abstract III) Clinical practice guidelines: DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux
More informationA PROVEN TREATMENT FOR CHRONIC REFLUX
A PROVEN TREATMENT FOR CHRONIC REFLUX This booklet is for patients who have discussed the LINX Reflux Management System during a consultation with their surgeon. It will answer some of the questions that
More informationEsomeprazole versus omeprazole for the eradication of Helicobacter pylori infection
International Journal of Community Medicine and Public Health Ageeli R et al. Int J Community Med Public Health. 2018 Jul;5(7):2686-2691 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original Research
More informationSymptom Characteristics and Psychosomatic Profiles in Different Spectrum of Gastroesophageal Reflux Disease
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 165-169 ORiginal Article Symptom Characteristics and Psychosomatic Profiles in Different Spectrum of Gastroesophageal Reflux Disease Chul-Hyun Lim, Myung-Gyu
More informationGastroesophageal reflux disease (GERD) is a common chronic
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:743 748 Efficacy of Esophageal Impedance/pH Monitoring in Patients With Refractory Gastroesophageal Reflux Disease, on and off Therapy JASON M. PRITCHETT,*
More informationMany patients with gastroesophageal reflux
... HEALTH ECONOMICS... Efficacy and Cost Effectiveness of Lansoprazole Versus Omeprazole in Maintenance Treatment of Symptomatic Gastroesophageal Reflux Disease Eva Vivian, PharmD; Anthony Morreale, PharmD,
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationMedical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Review)
Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Review) Donnellan C, Sharma N, Preston C, Moayyedi P This is a reprint of a Cochrane review,
More informationCoping with GERD Survey Results
Coping with GERD/ Survey Results MedicineNet Health Research Survey Report Coping with GERD Survey Results Prepared by MedicineNet.com May 2005 All Rights Reserved http://www.medicinenet.com/gerd_health_report/article.htm
More informationThe PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures
The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off
More informationReview article: management of mild and severe gastro-oesophageal reflux disease
Aliment Pharmacol Ther 2003; 17 (Suppl. 2): 52 56. Review article: management of mild and severe gastro-oesophageal reflux disease G. N. J. TYTGAT Department of Gastroenterology and Hepatology, Academic
More informationMISCONCEPTION OF HEART ATTACK PAIN WITH HEART BURN - HOW COMMON IS IT? Sehrish Khan, Rizwan Aziz Memon, Muhammad Farhan Khan, Mudassir Iqbal Dar
Pak Heart J ORIGINAL ARTICLE MISCONCEPTION OF HEART ATTACK PAIN WITH HEART BURN - HOW COMMON IS IT? 1 2 3 4 Sehrish Khan, Rizwan Aziz Memon, Muhammad Farhan Khan, Mudassir Iqbal Dar 1 Dow Medical College,
More informationHistological correlates of gastro esophageal reflux disease in South Indian population
International Journal of Research in Medical Sciences Ramasamy J et al. Int J Res Med Sci. 2016 Jun;4(6):1849-1854 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161441
More informationQOLRAD QUESTIONNAIRE FOR PATIENTS WITH SYMPTOMS OF HEARTBURN PLEASE READ THIS CAREFULLY BEFORE ANSWERING THE QUESTIONS
QOLRAD QUESTIONNAIRE FOR PATIENTS WITH SYMPTOMS OF HEARTBURN PLEASE READ THIS CAREFULLY BEFORE ANSWERING THE QUESTIONS On the following pages you will find some questions asking about how you have been
More informationTesting the measurement equivalence of electronically migrated patient-reported outcome (PRO) instruments: Challenges and Solutions
Testing the measurement equivalence of electronically migrated patient-reported outcome (PRO) instruments: Challenges and Solutions Sonya Eremenco, Evidera, Inc., Bethesda, MD, USA Diane Wild, ICON, Oxford,
More informationGastroesophageal reflux disease. The case for improving patient education in primary care
Original Research Gastroesophageal reflux disease: The case for improving patient education in primary care This study reveals that something as simple as knowing when to take GERD medication is compromised
More information